Investigational drug · Phase 3
nacubactam
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
4
Any phase or sponsor naming "nacubactam"
First trial start
2023
May 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "nacubactam", any sponsor or status.
Conditions studied
As listed on its trial records.
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
- Hospital-acquired Bacterial Pneumonia
- Ventilator-associated Bacterial Pneumonia
- Complicated Intra-abdominal Infection
- cUTI
- AP
Approved drugs for the same conditions: Urinary tract infection · Pneumonia · Infectious disease and vaccines · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "nacubactam" as an intervention, largest first.
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05887908 · 614 participants · Start May 23, 2023 · Primary completion Nov 22, 2024
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI and 1 more
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Silistra, Bulgaria · 61 sites in all
- P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant EnterobacteralesPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05905055 · 126 participants · Start Sep 22, 2023 · Primary completion Sep 1, 2025
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; Hospital-acquired Bacterial Pneumonia and 2 more
Sites: Changsha, China; Chongqing, China; Fuyang, China · 54 sites in all
Meiji Seika Pharma Co., Ltd.Industry
NCT02134834 · 40 participants · Start May 2014 · Primary completion Aug 2014
Drug: OP0595; Placebo · For: Healthy Volunteers; Bacterial Infections
Sites: Perth, Australia
- A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy ParticipantsCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03182504 · 21 participants · Start Jun 15, 2017 · Primary completion Aug 10, 2017
Drug: nacubactam; meropenem · For: Gram-negative Bacterial Infections
Sites: Phoenix, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- Correction: Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects.
Qiu H, Wu T, Diao L, et al. · Clin Exp Med 2026
- Efficacy of new antimicrobial agents against carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacterales in Japan: national genomic surveillance (JARBS 2.0) study.
Kitamura N, Yano H, Kawakami S, et al. · J Antimicrob Chemother 2026
- Cefepime 2.0: Upgrading β-Lactamase Inhibitor Use.
De Rosa FG, Lupia T, Fornari V, et al. · Microorganisms 2026
- In vitro activities of aztreonam/nacubactam and cefepime/nacubactam against a global collection of molecularly characterized Enterobacterales isolates carrying carbapenemases: a global antimicrobial resistance surveillance study from 2021 to 2023.
Estabrook M, Suzuki E, Shimizu A, et al. · JAC Antimicrob Resist 2026
- Characterizing the V516M penicillin-binding protein 2 (PBP2) mutation causing zidebactam resistance in Pseudomonas aeruginosa.
Sastre-Femenia MÀ, Gomis-Font MA, Fernández-Muñoz A, et al. · Antimicrob Agents Chemother 2026
- Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants.
Morita J, Sato H, Sumiya M, et al. · Antimicrob Agents Chemother 2026
Also in development for Complicated Urinary Tract Infection
- co-administration of aztreonamPhase 32 trials
Meiji Seika Pharma Co., Ltd. · Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia
- co-administration of cefepimePhase 32 trials
Meiji Seika Pharma Co., Ltd. · Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia
- antibioticsPhase 23 trials
TenNor Therapeutics (Zhongshan) Limited · Prosthetic Joint Infection (PJI), Periprosthetic Joint Infection (PJI), Acute Pyelonephritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.